Juno Therapeutics stock drops 5% after BTIG downgrades to sell
Juno Therapeutics Inc. shares dropped 5.2% in premarket trade Thursday after BTIG downgraded it to sell from neutral, with a $12 price target. Juno shares closed at $23.73 on Wednesday. The company is "trailing" competitors like Kite Pharma Inc. and Novartis AG to market and there is "little demonstrative proof" that Juno drugs work better or have fewer life-threatening side effects, BTIG analyst Dane Leone said. The company's lack of progress casts questions about its management, Leone said... Читать дальше...